EmmaMurray

Associate

Chicago + 1.312.269.1536

Connect:

Share

Emma Murray focuses her practice in the area of intellectual property disputes, with an emphasis on patent litigation in district courts around the country and post-grant proceedings at the United States Patent and Trademark Office. Emma represents companies in a variety of patent matters, including those in the biotechnology, pharmaceutical, and medical device industries.

Emma maintains an active pro bono practice and has represented several clients seeking asylum in immigration proceedings as part of the Firm's Laredo Project.

Experience

  • Merck asserts patent infringement claims under Hatch-Waxman Act relating to Bridion® against 16 generic drug makersJones Day is representing Merck & Co., Inc. in Hatch-Waxman patent infringement actions against 16 generic drug maker defendant groups, relating to the defendant groups' submissions of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of Bridion®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.
  • R.J. Reynolds wins major patent dispute at ITC involving tobacco heating and vaping productsJones Day's client Reynolds prevailed against competitors Philip Morris Products S.A. ("Philip Morris") and Altria Client Services LLC ("Altria") in a patent infringement dispute before the International Trade Commission (ITC) involving tobacco heating and vaping products.
  • FirstEnergy subsidiary sold interest in New Jersey hydroelectric facility to Yards Creek Energy LLCJones Day advised Jersey Central Power & Light Company, a regulated utility and subsidiary of FirstEnergy Corp., a diversified energy holding company, on the sale of its 50% undivided interest in the Yards Creek Pumped Storage Hydroelectric Facility (the "Yards Creek Facility") to Yards Creek Energy LLC ("LS Power"), a subsidiary of LS Power Development, LLC.
  • Global systemically important bank (GSIB) conducts risk assessment to determine impact of LIBOR transition on enterprise-wide portfoliosJones Day is advising a GSIB with respect to enterprise-wide portfolios impacted by the LIBOR transition, including conducting portfolio-wide risk impact assessments, analyzing various consumer products, and developing litigation contingency plans.
    • View All

    November 2019 Blogs

    Fed. Cir. Dissent: Opening Brief Lacking Appointments Clause Mention Still Eligible for Remand, PTAB Litigation Blog

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.